Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
A series of key leadership changes have been announced on Tuesday at Dyne Therapeutics, a muscle disease company developing therapeutics for people living with genetically-driven diseases. 3 September 2024
Inflammation and immunology (I&I) specialist Zenas BioPharma has named Jennifer Fox as its chief business officer and chief financial officer and Tanya Fischer as head of research and development and chief medical officer. 4 December 2023
Swiss clinical-stage biotech AC Immune today announced the appointment, effective January, 2024, of Dr Madiha Derouazi as chief scientific officer. 1 December 2023
British biotech Levicept has appointed Eliot Forster as chief executive, with the company’s founder, Simon Westbrook, taking up the role of chief scientific officer. 30 November 2023
Belgian biotech Agomab Therapeutics today announced the appointment of Dr Angelika Jahreis as an independent non-executive director to its board of directors, while Andrea Sáez will join Agomab’s executive leadership team as chief development officer. 29 November 2023
US ophthalmic drug developer Ocuphire Pharma has announced the appointment of Joseph (Joe) Schachle into the newly created role of chief operating officer (COO), effective today. 27 November 2023
US biotech Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, has announced changes to its executive leadership team. 24 November 2023
Utah, USA-based biotech Halia Therapeutics has appointed Lisa Shamon as vice president of regulatory affairs and Xianne Penny as a senior medical director. 17 November 2023
UK-based eXmoor pharma, a cell and gene therapy (CGT) manufacturing partner, has announced the hiring of Matthew Paterson as the company’s first chief commercial officer. 15 November 2023
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023
US clinical-stage liver disease specialist Madrigal Pharmaceuticals’ shares gained 1.8% to $138.84 on Friday, as it announced new data from the Phase III MAESTRO-NASH trial demonstrating broad treatment effects of resmetirom. 13 November 2023
Poolbeg Pharma has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. 10 November 2023
Israeli generics giant Teva Pharmaceutical Industries has reported its latest quarterly financial results against a backdrop of war in its home region. 8 November 2023
American biopharma company Vertex Pharmaceuticals has announced strong third quarter financial results and raised its guidance for product revenues in 2023. 7 November 2023
Thomas Cueni, the director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and secretary of the Biopharmaceutical CEO Roundtable (BCR), is set to retire in April 2024. 6 November 2023
US ophthalmic drug developer Ocuphire Pharma has appointed Dr George Magrath, as chief executive and member of the board of directors, effective today. 2 November 2023